Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (IPSC) has appointed biotechnology executive Joseph Truitt to its Board of Directors.
Truitt is Chief Executive Officer and a director of iECURE, serves as Chairman of the Board of Larimar Therapeutics (LRMR), and sits on the Board of Code Biotherapeutics. He previously held senior leadership roles at BioSpecifics Technologies and Achillion Pharmaceuticals, both acquired by larger pharmaceutical companies.
The appointment comes as Century advances CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, toward an IND submission targeted for the fourth quarter of 2026 after an FDA pre-IND meeting that aligned on key development elements, and prepares CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, for anticipated clinic entry in 2026. Both candidates use the company’s Allo-Evasion™ 5.0 platform.
Century Therapeutics (NASDAQ: IPSC) reported second quarter 2026 results and development progress for its iPSC-derived cell therapy pipeline. The company completed a pre-IND meeting with the FDA for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, gaining general alignment on the nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, keeping an IND filing on track for 4Q 2026 and initial clinical data expected in 2H 2027.
Century also plans to advance CNTY-308, a CD19-targeted CAR-iT cell therapy, into the clinic in 2026. Cash, cash equivalents and investments were $197.2 million as of June 30, 2026, providing runway into 1Q 2029. Q2 R&D and G&A expenses declined year over year, while the company recorded a Q2 net loss of $34.6 million and an accumulated deficit of $848.1 million.
Century Therapeutics (NASDAQ: IPSC) will present preclinical data on its iPSC-derived islet replacement therapy CNTY-813 at two major diabetes meetings in 2026.
Oral presentations are scheduled at EASD 2026 on October 2 in Milan and the Breakthrough T1D Clinical & Research Congress 2026 on October 9 in Philadelphia.
Century Therapeutics (NASDAQ: IPSC) reported new preclinical data for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, at ADA 2026. In diabetic mice, CNTY-813 restored and maintained normoglycemia for over eight months and showed no tumorigenesis in more than 140 animals.
Allo-Evasion™ 5.0 edits preserved glucose control and enabled immune evasion in humanized mouse models without immunosuppression. Century has established a Phase 1 manufacturing process with consistent endocrine purity and targets a CNTY-813 IND submission in 4Q 2026 and initial clinical data in 2H 2027.
Century Therapeutics (NASDAQ: IPSC) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $217.0 million on March 31, 2026, with a projected cash runway into Q1 2029. Net loss was $21.6 million.
CNTY‑813 remains on track for an IND in 4Q 2026 with initial clinical data expected in 2H 2027, while CNTY‑308 is expected to enter clinical testing in 2026. The company also completed a $135 million private placement in January 2026 and reduced R&D and G&A expenses year over year.
Century Therapeutics (NASDAQ: IPSC) will deliver an oral presentation at the American Diabetes Association 86th Scientific Sessions on June 8, 2026, highlighting CNTY-813, an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for type 1 diabetes.
The company says CNTY-813 is on track for an IND submission in 4Q 2026. Presentation details: oral talk by Leonardo Velazco-Cruz, PhD, abstract/session number 1318-OR, 2:45–3:00 p.m. CT.
Century Therapeutics (NASDAQ: IPSC) reported full-year 2025 results and pipeline progress on March 12, 2026. Key news: CNTY-813 is in IND-enabling studies with an IND submission expected in 4Q 2026 and initial clinical data anticipated in 2H 2027. CNTY-308 is advancing toward clinical entry in 2026. The company completed an oversubscribed $135 million private placement and says cash runway is extended into 1Q 2029. 2025 financials: cash and investments of $117.1 million, collaboration revenue of $109.2 million, R&D $95.7 million, G&A $24.0 million, and net loss of $9.6 million.
Century Therapeutics (NASDAQ: IPSC) will participate in two investor conferences in March 2026 with scheduled fireside chats: TD Cowen on March 4, 2026 at 9:50 a.m. ET in Boston and Leerink Partners on March 10, 2026 at 4:20 p.m. ET in Miami.
A live webcast will be available on Century's Investors page and archived replays will remain available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC) secured an oversubscribed private placement expected to raise approximately $135 million in initial gross proceeds, led by TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW, Venrock Healthcare Capital Partners and the T1D Fund.
The financing will issue ~117.39 million common shares (or pre-funded warrants) and warrants to purchase ~58.70 million shares at a purchase price of $1.15 per share, with accompanying warrants exercisable at $2.60. Full warrant exercise would provide an additional ~$153 million.
Century expects the offering to close on Jan 9, 2026, estimates the proceeds extend cash runway to Q1 2029, anticipates an IND submission in 2026 for CNTY-813 and initial clinical data in 2027. Proceeds are for development of CNTY-813 and general corporate purposes.
Century Therapeutics (NASDAQ: IPSC) appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors effective December 9, 2025.
Dr. Lee will join the Audit and Compensation Committees; Dr. Murphy will join the Compensation and Nominating and Corporate Governance Committees. The company said the appointments support execution of its iPSC-derived cell therapy programs, including CNTY-813 for type 1 diabetes, and add capital-formation, corporate development and life-science investment experience to the board.